

# Andreas Wollenberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7265803/publications.pdf>

Version: 2024-02-01

208  
papers

18,527  
citations

14655

66  
h-index

13379

130  
g-index

251  
all docs

251  
docs citations

251  
times ranked

9973  
citing authors

#	ARTICLE	IF	CITATIONS
1	Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2016, 375, 2335-2348.	27.0	1,467
2	Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 657-682.	2.4	727
3	Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 850-878.	2.4	519
4	Guidelines for treatment of atopic eczema (atopic dermatitis) Part I. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1045-1060.	2.4	495
5	Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon) 1. <i>Journal of Biological Chemistry</i> , 1987, 262, 10784-10788.	8.5	473
6	Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2017, 376, 826-835.	27.0	470
7	Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 336-349.	2.9	465
8	Mutations in CGI-58, the Gene Encoding a New Protein of the Esterase/Lipase/Thioesterase Subfamily, in Chanarin-Dorfman Syndrome. <i>American Journal of Human Genetics</i> , 2001, 69, 1002-1012.	6.2	435
9	Plasmacytoid Dendritic Cells: A New Cutaneous Dendritic Cell Subset with Distinct Role in Inflammatory Skin Diseases. <i>Journal of Investigative Dermatology</i> , 2002, 119, 1096-1102.	0.7	384
10	Safety and Efficacy of 1 Year of Tacrolimus Ointment Monotherapy in Adults With Atopic Dermatitis. <i>Archives of Dermatology</i> , 2000, 136, 999.	1.4	368
11	Immunomorphological and Ultrastructural Characterization of Langerhans Cells and a Novel, Inflammatory Dendritic Epidermal Cell (IDEC) Population in Lesional Skin of Atopic Eczema. <i>Journal of Investigative Dermatology</i> , 1996, 106, 446-453.	0.7	364
12	ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 729-747.	2.4	329
13	Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1176-1193.	2.4	316
14	Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 135-141.	2.9	294
15	Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. <i>British Journal of Dermatology</i> , 2021, 184, 437-449.	1.5	289
16	Conjunctivitis in dupilumab clinical trials. <i>British Journal of Dermatology</i> , 2019, 181, 459-473.	1.5	288
17	Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. <i>British Journal of Dermatology</i> , 2020, 183, 242-255.	1.5	277
18	Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet</i> , 2020, 396, 255-266.	13.7	273

#	ARTICLE	IF	CITATIONS
19	Viral infections in atopic dermatitis Pathogenic aspects and clinical management. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 667-674.	2.9	271
20	Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 198-205.	1.2	267
21	Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon- $\gamma$ -expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. <i>Gut</i> , 2014, 63, 567-577.	12.1	267
22	ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 317-328.	2.4	264
23	Cathelicidin deficiency predisposes to eczema herpeticum. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 836-841.	2.9	252
24	The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2004, 59, 1318-1325.	5.7	244
25	Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 547-555.	2.9	231
26	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2717-2744.	2.4	220
27	Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1282-1293.	1.2	214
28	Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 742-750.	5.7	211
29	Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 1114-1121.	5.7	201
30	Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1121-1130.e7.	2.9	195
31	Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. <i>New England Journal of Medicine</i> , 2020, 382, 706-716.	27.0	189
32	Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 173-182.	2.9	183
33	Expression and Function of the Mannose Receptor CD206 on Epidermal Dendritic Cells in Inflammatory Skin Diseases. <i>Journal of Investigative Dermatology</i> , 2002, 118, 327-334.	0.7	181
34	When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 623-633.	1.2	170
35	Towards global consensus on outcome measures for atopic eczema research: results of the <sc>HOME II</sc> meeting. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 1111-1117.	5.7	169
36	Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 519-525.	2.9	164

#	ARTICLE	IF	CITATIONS
37	European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1059-1065.	2.4	150
38	Management of Difficult-to-Treat Atopic Dermatitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2013, 1, 142-151.	3.8	143
39	Diagnostic approach to the hyper-IgE syndromes: Immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 611-617.e1.	2.9	140
40	Dupilumab for treatment of atopic dermatitis. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 467-474.	3.1	135
41	Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab—clinical characteristics and treatment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1778-1780.e1.	3.8	132
42	Atopic dermatitis: from the genes to skin lesions. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2000, 55, 205-213.	5.7	129
43	Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. <i>Journal of the American Academy of Dermatology</i> , 2001, 45, 736-743.	1.2	127
44	Position paper on diagnosis and treatment of atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2005, 19, 286-295.	2.4	122
45	Proactive therapy of atopic dermatitis — an emerging concept. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 276-278.	5.7	121
46	Atopy patch test reactions show a rapid influx of inflammatory dendritic epidermal cells in patients with extrinsic atopic dermatitis and patients with intrinsic atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 869-874.	2.9	119
47	Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). <i>British Journal of Dermatology</i> , 2016, 175, 69-79.	1.5	115
48	Long Term Treatment Concepts and Proactive Therapy for Atopic Eczema. <i>Annals of Dermatology</i> , 2012, 24, 253.	0.9	114
49	Phacomatosis Pigmentokeratolica Is Caused by a Postzygotic HRAS Mutation in a Multipotent Progenitor Cell. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1998-2003.	0.7	105
50	Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. <i>Annals of Oncology</i> , 2011, 22, 524-535.	1.2	104
51	The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. <i>British Journal of Dermatology</i> , 2020, 182, 1331-1342.	1.5	102
52	European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e241-e242.	2.4	99
53	Psychodermatological aspects of atopic dermatitis. <i>British Journal of Dermatology</i> , 2014, 170, 38-43.	1.5	96
54	Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). <i>British Journal of Dermatology</i> , 2018, 178, e332-e341.	1.5	96

#	ARTICLE	IF	CITATIONS
55	Phenotyping of epidermal dendritic cells: Clinical applications of a flow cytometric micromethod. <i>Cytometry</i> , 1999, 37, 147-155.	1.8	93
56	Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). <i>British Journal of Dermatology</i> , 2020, 182, 1120-1135.	1.5	92
57	Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 845-853.e3.	2.9	87
58	Atopic dermatitis, <sc>STAT</sc>3 and <sc>DOCK</sc>8 hyper-IgE syndromes differ in IgE-based sensitization pattern. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 943-953.	5.7	86
59	European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1644-1659.	2.4	85
60	Langerhans cell phenotyping: a new tool for differential diagnosis of inflammatory skin diseases. <i>Lancet, The</i> , 1995, 346, 1626-1627.	13.7	84
61	Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 742-750.	5.7	83
62	Atopic dermatitis: pathogenetic mechanisms. <i>Clinical and Experimental Dermatology</i> , 2000, 25, 530-534.	1.3	79
63	Phenotyping of epidermal dendritic cells allows the differentiation between extrinsic and intrinsic forms of atopic dermatitis. <i>British Journal of Dermatology</i> , 2000, 143, 1193-1198.	1.5	76
64	Innate Immunity in Atopic Dermatitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2011, 41, 272-281.	6.5	76
65	Human keratinocytes release the endogenous beta-galactoside-binding soluble lectin immunoglobulin E (IgE-binding protein) which binds to Langerhans cells where it modulates their binding capacity for IgE glycoforms.. <i>Journal of Experimental Medicine</i> , 1993, 178, 777-785.	8.5	73
66	Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. <i>Journal of Dermatological Treatment</i> , 2020, 31, 606-614.	2.2	72
67	Smallpox, vaccination and adverse reactions to smallpox vaccine. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2004, 4, 271-275.	2.3	66
68	Unopposed IL-36 Activity Promotes Clonal CD4+ T-Cell Responses with IL-17A Production in Generalized Pustular Psoriasis. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1338-1347.	0.7	64
69	Lessons from atopy patch testing in Atopic Dermatitis. <i>Current Allergy and Asthma Reports</i> , 2004, 4, 285-9.	5.3	61
70	Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 137-143.	2.9	61
71	In situ expression of the costimulatory molecules CD80 and CD86 on Langerhans cells and inflammatory dendritic epidermal cells (IDEC) in atopic dermatitis. <i>Archives of Dermatological Research</i> , 2001, 293, 448-454.	1.9	60
72	Clinical and immunologic reactivity to aeroallergens in intrinsic atopic dermatitis patients. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 195-197.	2.9	59

#	ARTICLE	IF	CITATIONS
73	Human and computational models of atopic dermatitis: A review and perspectives by an expert panel of the International Eczema Council. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 36-45.	2.9	58
74	Current Aspects of Innate and Adaptive Immunity in Atopic Dermatitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2007, 33, 35-44.	6.5	54
75	A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease – strategies for optimizing treatment outcome. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2253-2263.	2.4	54
76	The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. <i>Experimental Dermatology</i> , 2019, 28, 3-10.	2.9	51
77	Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1224-1231.	2.4	50
78	Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence. <i>World Allergy Organization Journal</i> , 2021, 14, 100519.	3.5	48
79	Treatment of atopic eczema with oral alitretinoin. <i>British Journal of Dermatology</i> , 2010, 162, 217-218.	1.5	47
80	Global Allergy Forum and 3rd Davos Declaration 2015. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 588-592.	5.7	47
81	A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 34-40.	1.2	45
82	A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. <i>Experimental Dermatology</i> , 2008, 17, 790-792.	2.9	44
83	Contact sensitization in patients with suspected cosmetic intolerance: results of the <scp>IVDK</scp> 2006–2011. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1071-1081.	2.4	44
84	Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. <i>British Journal of Dermatology</i> , 2022, 186, 453-465.	1.5	43
85	Atopic Dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019. <i>International Archives of Allergy and Immunology</i> , 2019, 178, 207-218.	2.1	42
86	Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1263-1272.	2.4	41
87	Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE AD7 Phase 3 randomized trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1543-1552.	2.4	41
88	Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 958-960.	2.4	40
89	Cutaneous Side Effects of New Antitumor Drugs. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2012, 109, 133-40.	0.9	40
90	Pollen Grains Induce a Rapid and Biphasic Eczematous Immune Response in Atopic Eczema Patients. <i>International Archives of Allergy and Immunology</i> , 2008, 145, 213-223.	2.1	39

#	ARTICLE	IF	CITATIONS
91	Proaktive Therapie des atopischen Ekzems – ein evidenzbasiertes Therapiekonzept mit verhaltenstherapeutischem Hintergrund. JDDG - Journal of the German Society of Dermatology, 2009, 7, 117-121.	0.8	39
92	Key findings to expedite the diagnosis of hyper-IgE syndromes in infants and young children. Pediatric Allergy and Immunology, 2016, 27, 177-184.	2.6	39
93	Food-Related Contact Dermatitis, Contact Urticaria, and Atopy Patch Test with Food. Clinical Reviews in Allergy and Immunology, 2019, 56, 19-31.	6.5	39
94	Long-lasting "Christmas Tree Rash" in an Adolescent: Isotopic Response of Indeterminate Cell Histiocytosis in Pityriasis Rosea?. Acta Dermato-Venereologica, 2002, 82, 288-291.	1.3	37
95	Implementation of dupilumab in routine care of atopic eczema: results from the German national registry <scp>TREAT</scp> germany. British Journal of Dermatology, 2020, 183, 382-384.	1.5	37
96	Evolution of Conventional Therapy in Atopic Dermatitis. Immunology and Allergy Clinics of North America, 2010, 30, 351-368.	1.9	36
97	Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology, 2008, 159, 1322-1330.	1.5	35
98	Atopic dermatitis - all you can do from the outside. British Journal of Dermatology, 2014, 170, 19-24.	1.5	35
99	Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review. Journal of the American Academy of Dermatology, 2016, 75, 1038-1044.	1.2	35
100	Eczema molluscatum in tacrolimus treated atopic dermatitis. European Journal of Dermatology, 2004, 14, 73-4.	0.6	35
101	Pimecrolimus cream (1%) efficacy in perioral dermatitis ? results of a randomized, double-blind, vehicle-controlled study in 40 patients. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 070525001847013-???	2.4	34
102	Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI-16) analysis of randomized phase 2B study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1562-1568.	2.4	33
103	Proactive therapy of atopic eczema – an evidence-based concept with a behavioral background. JDDG - Journal of the German Society of Dermatology, 2009, 7, 117-121.	0.8	32
104	Eczema Herpeticum. Chemical Immunology and Allergy, 2012, 96, 89-95.	1.7	32
105	Effects of a protein-free oat plantlet extract on microinflammation and skin barrier function in atopic dermatitis patients. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1-15.	2.4	32
106	Recurrent eczema herpeticum – a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1074-1079.	2.4	32
107	Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 577-587.	2.4	31
108	Dorfman-Chanarin Syndrome in a Turkish Kindred: Conductor Diagnosis Requires Analysis of Multiple Eosinophils. Acta Dermato-Venereologica, 2000, 80, 39-43.	1.3	30

#	ARTICLE	IF	CITATIONS
109	Atypical Forms of Hand, Foot, and Mouth Disease: A Prospective Study of 47 Italian Children. <i>Pediatric Dermatology</i> , 2016, 33, 429-437.	0.9	30
110	Update of the S2k guideline on atopic dermatitis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 151-168.	0.8	30
111	Difficult to control atopic dermatitis. <i>World Allergy Organization Journal</i> , 2013, 6, 6.	3.5	29
112	Atopic dermatitis and skin allergies - update and outlook. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 1509-1519.	5.7	29
113	2020 European guideline on the management of genital molluscum contagiosum. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 17-26.	2.4	29
114	Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 195-202.	0.8	28
115	Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1432-1449.	2.4	28
116	Phacomatosis Pigmentokeratotica (Happle) in a 23-Year-Old Man. <i>Acta Dermato-Venereologica</i> , 2002, 82, 55-57.	1.3	27
117	Management of dupilumab-associated conjunctivitis in atopic dermatitis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 488-491.	0.8	27
118	European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e308-e311.	2.4	27
119	Characterization of the protein tyrosine phosphatase CD45 on human epidermal Langerhans cells. <i>European Journal of Immunology</i> , 1995, 25, 317-321.	2.9	26
120	Skin diseases following a Christmas tree pattern. <i>Clinics in Dermatology</i> , 2011, 29, 189-194.	1.6	26
121	Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 742-50.	5.7	26
122	Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1521-1530.	2.2	25
123	Patch Testing for Noncontact Dermatitis: The Atopy Patch Test for Food and Inhalants. <i>Current Allergy and Asthma Reports</i> , 2013, 13, 539-544.	5.3	24
124	Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e362-e365.	2.4	24
125	Evaluation of antimicrobial textiles for atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 384-390.	2.4	23
126	Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis – A pooled analysis of trial data. <i>Pediatric Dermatology</i> , 2022, 39, 187-196.	0.9	23



#	ARTICLE	IF	CITATIONS
127	IL-10 inhibits ICAM-1 expression on human Langerhans cells but not on keratinocytes, dermal endothelial cells or fibroblasts. Archives of Dermatological Research, 1998, 290, 477-482.	1.9	22
128	Isotopic response, Koebner phenomenon and Renbark phenomenon following herpes zoster. Journal of Dermatology, 2011, 38, 1058-1061.	1.2	22
129	European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e839-e842.	2.4	22
130	Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. Current Opinion in Investigational Drugs, 2002, 3, 708-12.	2.3	22
131	Enhanced Expression and Activity of Protein-tyrosine Kinases Establishes a Functional Signaling Pathway Only in Fc̳RIIhigh Langerhans Cells from Atopic Individuals. Journal of Investigative Dermatology, 2002, 119, 804-811.	0.7	20
132	Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. European Journal of Medical Research, 2012, 17, 4.	2.2	20
133	Immunological and molecular targets of atopic dermatitis treatment. British Journal of Dermatology, 2014, 170, 7-11.	1.5	20
134	Beneficial IFN-̳ treatment of tumorous herpes simplex blepharoconjunctivitis in dedicator of cytokinesis 8 deficiency. Journal of Allergy and Clinical Immunology, 2014, 133, 1456-1458.	2.9	19
135	Cost of illness of atopic dermatitis in Germany: data from dermatology routine care. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1346-1356.	2.4	19
136	Pathomechanism of dupilumab-associated inflammatory eye symptoms. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e435-e436.	2.4	18
137	Evaluation of hand hygiene and onset of hand eczema after the outbreak of SARS-CoV-2 in Munich. European Journal of Dermatology, 2020, 30, 668-673.	0.6	18
138	Multiple superficial basal cell carcinomas (basalomatosis) following cobalt irradiation. British Journal of Dermatology, 1995, 133, 644-646.	1.5	17
139	A practical approach to ichthyoses with systemic manifestations. Clinical Genetics, 2017, 91, 799-812.	2.0	17
140	Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials. Journal of Dermatological Treatment, 2022, 33, 266-277.	2.2	17
141	Face mask dermatitis due to compulsory facial masks during the SARS-CoV-2 pandemic: data from 550 health care and non-health care workers in Germany. European Journal of Dermatology, 2021, 31, 199-204.	0.6	17
142	Demonstration of the low-affinity IgE receptor Fc̳RII/CD23 in psoriatic epidermis: inflammatory dendritic epidermal cells (IDEC) but not Langerhans cells are the relevant CD1a-positive cell population. Archives of Dermatological Research, 1998, 290, 517-521.	1.9	16
143	Scoring of Skin Lesions with the Perioral Dermatitis Severity Index (PODSI). Acta Dermato-Venereologica, 2006, 86, 251-252.	1.3	16
144	Leser-Trélat sign in metastasized malignant melanoma. European Archives of Oto-Rhino-Laryngology, 2009, 266, 297-299.	1.6	16

#	ARTICLE	IF	CITATIONS
145	Defining and measuring "eczema control": an international qualitative study to explore the views of those living with and treating atopic eczema. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1124-1132.	2.4	16
146	Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 576-583.e4.	1.0	16
147	Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib. <i>Dermatitis</i> , 2021, 32, S53-S61.	1.6	15
148	Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. <i>Paediatric Drugs</i> , 2021, 23, 515-527.	3.1	15
149	Phenotyping of epidermal dendritic cells: clinical applications of a flow cytometric micromethod. <i>Cytometry</i> , 1999, 37, 147-55.	1.8	15
150	Management kutaner Nebenwirkungen von EGFR-Inhibitoren: Empfehlungen eines deutschen Expertengremiums für den primär behandelnden Arzt. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 195-203.	0.8	14
151	Increased prevalence of irritant hand eczema in health care workers in a dermatological clinic due to increased hygiene measures during the SARS-CoV-2 pandemic. <i>European Journal of Dermatology</i> , 2021, 31, 392-395.	0.6	14
152	Periorale Dermatitis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 422-428.	0.8	13
153	Inborn Error of Immunity or Atopic Dermatitis: When to be Concerned and How to Investigate. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1501-1507.	3.8	13
154	Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis*. <i>British Journal of Dermatology</i> , 2022, 186, 285-294.	1.5	13
155	Dupilumab for the treatment of adolescents with atopic dermatitis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 641-650.	3.0	12
156	Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD. <i>Dermatology and Therapy</i> , 2021, 11, 221-233.	3.0	12
157	Neurogenic inflammation and colliquative lymphadenitis with persistent orthopox virus DNA detection in a human case of cowpox virus infection transmitted by a domestic cat. <i>British Journal of Dermatology</i> , 2015, 173, 535-539.	1.5	11
158	Topical immunomodulatory agents and their targets in inflammatory skin diseases. <i>Transplantation Proceedings</i> , 2001, 33, 2212-2216.	0.6	10
159	Perioral dermatitis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 422-427.	0.8	10
160	An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1486-1496.	2.4	10
161	Photoallergic contact dermatitis due to treatment of pulmonary fibrosis with pirfenidone. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 370-371.	2.4	9
162	Chronic Hand Eczema Guidelines From an Expert Panel of the International Eczema Council. <i>Dermatitis</i> , 2021, 32, 319-326.	1.6	9

#	ARTICLE	IF	CITATIONS
163	Quality of care in atopic dermatitis – a position statement by the European Task Force on Atopic Dermatitis (<scp>ETFAD</scp>). Journal of the European Academy of Dermatology and Venereology, 2020, 34, e136-e138.	2.4	8
164	Atopic dermatitis: disease characteristics and comorbidities in smoking and non-smoking patients from the TREATgermany registry. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 413-421.	2.4	8
165	EcÉRI Expressing Dendritic Cells: The Missing Link in the Pathophysiology of Atopic Dermatitis ?. Journal of Dermatology, 2000, 27, 698-699.	1.2	7
166	Efficacy of a skin care cream with TRPV1 inhibitor 4-tert-butylcyclohexanol in the topical therapy of perioral dermatitis. Journal of Cosmetic Dermatology, 2020, 19, 1409-1414.	1.6	7
167	Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers. JDDG - Journal of the German Society of Dermatology, 2012, 10, 559-562.	0.8	6
168	Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1507-1516.	3.3	6
169	Dapsone treatment for eosinophilic annular erythema. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e153-e154.	2.4	6
170	Management der Dupilumab-assozierten Konjunktivitis beim atopischen Ekzem. JDDG - Journal of the German Society of Dermatology, 2019, 17, 488-492.	0.8	6
171	Perioral Dermatitis Successfully Treated with Topical Ivermectin. Annals of Dermatology, 2019, 31, S27.	0.9	6
172	Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial. Journal of the American Academy of Dermatology, 2021, 84, 495-497.	1.2	6
173	Rat bite fever, a diagnostic challenge: case report and review of 29 cases. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1283-1287.	0.8	6
174	Tralokinumab in atopic dermatitis. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1435-1442.	0.8	6
175	Position statement on the role of nurses in therapeutic patient education in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2143-2148.	2.4	5
176	Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials. SKIN the Journal of Cutaneous Medicine, 2021, 5, s11.	0.3	5
177	Efficacy and Safety Results of a Drug-Free Cosmetic Fluid for Perioral Dermatitis: The Toleriane Fluide Efficacy in Perioral Dermatitis (TOLPOD) Study. Annals of Dermatology, 2014, 26, 462.	0.9	4
178	Linear patterns of the skin and their dermatoses. JDDG - Journal of the German Society of Dermatology, 2020, 18, 341-364.	0.8	4
179	Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis. Acta Dermato-Venereologica, 2022, 102, adv00726.	1.3	4
180	The Role of Dendritic Cells in Cutaneous Lupus Erythematosus. , 2005, , 283-295.		3

#	ARTICLE	IF	CITATIONS
181	Atopic Dermatitis in Infants and Toddlers: a Diagnostic Challenge in Daily Practice. Current Dermatology Reports, 2017, 6, 230-240.	2.1	3
182	Essentielle diagnostische Verfahren in der Dermatologie. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2001, , 499-505.	0.0	3
183	Perception of the coronavirus pandemic by patients with atopic dermatitis " Results from the TREATgermany registry. JDDG - Journal of the German Society of Dermatology, 2022, 20, 45-57.	0.8	3
184	Determinants of costs and benefits in atopic dermatitis routine care in Germany. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1450-1455.	2.4	3
185	Acne conglobata and Klinefelter's syndrome. British Journal of Dermatology, 1997, 136, 421-423.	1.5	2
186	Atopisches Ekzem. , 2018, , 549-568.		2
187	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 753-754.	3.8	2
188	Inflammatory Dendritic Epidermal Cells. , 2006, , 288-295.		1
189	Pustular erythema multiforme major associated with atypical pneumonia. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e502-e503.	2.4	1
190	Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, n/a-n/a.	5.7	1
191	Role of viruses. Series in Dermatological Treatment, 2008, , 69-76.	0.1	1
192	Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older. Dermatology and Therapy, 2021, 11, 1643-1656.	3.0	1
193	Atopic dermatitis and depressive symptoms. Results of the German national AD Registry TREATgermany. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
194	Urticaria haemorrhagica profunda. British Journal of Dermatology, 1997, 136, 108-11.	1.5	1
195	Sensitive skin: A relevant syndrome, be aware. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 3-5.	2.4	1
196	New Perspectives in the Treatment of Atopic Dermatitis in the Pediatric Population. Pediatric, Allergy, Immunology, and Pulmonology, 2016, 29, 189-195.	0.8	0
197	Topical Therapy of AD: How to Reach Better Results. Current Dermatology Reports, 2017, 6, 137-143.	2.1	0
198	Silver, silk, atopic eczema and the CLOTHES trial " reply to a letter. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e169.	2.4	0

#	ARTICLE	IF	CITATIONS
199	Reply to a correspondence addressing the European guideline for treatment of atopic eczema, functional textiles and the CLOTHES trial. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e153-e154.	2.4	0
200	Methotrexate in atopic eczema – Reply to a letter. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e155-e156.	2.4	0
201	Pharmacist recommendations regarding topical steroid use may contradict the standard of care in atopic dermatitis: An international, cross-sectional study. JAAD International, 2021, 4, 13-14.	2.2	0
202	The Intrinsic Type of Atopic Dermatitis Is Characterised by a Low Expression of the High-Affinity IgE Receptor Fc̳RI on Epidermal Dendritic Cells. , 2002, , 137-144.		0
203	Eczema herpeticum. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2005, , 181-185.	0.0	0
204	Therapie ungewöhnlicher Manifestationen und Komplikationen des atopischen Ekzems. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2009, , 143-147.	0.0	0
205	Kinderdermatologie. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2013, , 408-417.	0.0	0
206	Galenik – Praktische Tipps und Beispiele. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2013, , 392-398.	0.0	0
207	Atopisches Ekzem. , 2018, , 1-21.		0
208	Acne conglobata and Klinefelter's syndrome. British Journal of Dermatology, 1997, 136, 421-3.	1.5	0